Malin reports €9.52 per share intrinsic value, returns €150m to shareholders

Malin Corporation plc reported its intrinsic equity value per share declined to €9.52 as of June 30, 2025, from €10.36 at year-end 2024, with overall intrinsic value falling from €195.6 million to €41.3 million. This was primarily due to the strategic divestment of its Poseida stake for €103.4 million and a subsequent €150 million capital return to shareholders, which significantly reduced the share count to 4.34 million and depleted its cash reserves. While management highlighted the Poseida sale as a key milestone for shareholder value, the company also noted a downward revision to its Viamet valuation due to regulatory challenges.

Analysis

Malin Corporation plc has undergone a significant strategic transformation in the first half of 2025, marked by a substantial reduction in both scale and cash reserves. The company's intrinsic equity value per share declined to €9.52 from €10.36, while its total intrinsic equity value plummeted from €195.6 million to €41.3 million. This change was primarily driven by the divestment of its Poseida stake for €103.4 million and a subsequent €150 million capital return to shareholders. This capital return, executed via a share buyback, drastically reduced the issued share capital from 18.9 million to 4.3 million shares, which explains the relatively stable per-share value despite the large drop in total equity. However, the company's financial position has tightened considerably, with its cash balance falling from €62.1 million to €13.7 million by mid-year. Compounding the risk profile is a downward valuation revision of its interest in Viamet due to regulatory challenges, highlighting the uncertainty within its remaining life sciences portfolio. While there is potential upside from a contingent value right of up to $47.3 million from the Poseida sale, the company's low cash position against its €1.4 million H1 corporate operating expenses warrants close monitoring.

Key Decisions for Investors

• Investors should assess Malin's new, smaller profile, recognizing that future returns are now heavily dependent on a concentrated portfolio where key assets, like Viamet, are already facing regulatory headwinds.
• Given the cash position has fallen to €13.4 million, it is critical to monitor the company's cash burn rate and any announcements regarding future financing or asset monetization to sustain operations.
• The potential $47.3 million contingent payment from the Poseida sale represents a significant, albeit uncertain, catalyst that could provide non-dilutive funding, and its progress should be tracked closely.